We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.

Settings

Save and close

JAX Frontend Platform

Onco-Hu® Mouse Models

Unrivaled translational platforms for immuno-oncology.

REQUEST A QUOTE

[email protected] | 1.800.422.6423 (US) | 1.207.288.5845 (International)

What are Onco-Hu® mice?

Onco-Hu® models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells. The platform is based on NSG™ and NSG™-SGM3 transgenic mice, dualy engrafted with human CD34+ hematopoietic stem cells (HSCs) and clinically relevant PDX Live™ low passage tumors.

Advantages

As a robust pre-clinical tool for assessing proof-of-concept treatment strategies and evaluating the efficacy of immunotherapeutics, the Onco-Hu® platform better recapitulates human tumor and immune-cell interactions in vivo compared to existing models, allowing more improved physiological modeling of pathways important in therapeutic intervention.

  • Hematopoietic stem cells
  • Myeloid progenitor cells
  • CD33+ myeloid cells
  • Dendritic cells
  • Helper T cells
  • Cytotoxic cells
  • Treg cells
  • B cells

Revolutionizing pre-clinical research

We can run accelerated immuno-oncology studies for you. Our In Vivo Pharmacology Services offers optimized immuno-oncology efficacy studies to test anti-tumor responses using highly characterized Onco-Hu® models expressing high PD-L1 levels. These validated platforms support robust tumor growth and respond to check-point inhibitors, such as the anti-PD-1 receptor antibody pembrolizumab, and exhibit tumor infiltration of cytotoxic T cells and reduction of tumor growth rate (Li-Chin Yao, et al. 2015).

Figures: Onco-Hu® models engrafted with PDX Live™ clinically relevant breast, lung tumors and cell lines expressing PD-L1 allow evaluating the efficacy of immunomodulators—alone or in combination therapies—to treat cancer. Triple negative breast Onco-Hu® TM00098 responds to Keytruda. Lung cancer -Hu® TM00302 responds to checkpoint inhibitors Keytruda and Yervoy, compared to vehicle group.

PDX Seq

Cutting edge bioinformatics for preclinical oncology. Dig deeper to understand tumor response or resistance to your treatment.

Learn More

©2025 The Jackson Laboratory